
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is positioned for success with a variety of upcoming catalysts, including clinical data updates for their CD20-targeted allogeneic gamma delta CAR-T cell therapy in 1H26 and a potential registrational study in 2H26. With a reverse stock split to maintain listing requirements on the NASDAQ and a strong pipeline featuring ADI-001 and ADI-212, the current share price presents an attractive entry point for investors. However, there are risks to consider, such as potential failures to meet efficacy standards and longer enrollment and data presentation timelines.
Bears say
Adicet Bio is a clinical-stage biotechnology company that is currently facing several challenges. These include a relatively new approach to cell therapy, a potential decrease in probability of success for their main product candidate in autoimmune diseases, and risks associated with the regulatory approval process for novel treatments. Additionally, the company has faced financial concerns, with a recent reverse stock split and a decrease in price target due to a dilution of shares and a more conservative NPV valuation. These factors, along with potential manufacturing and currency risks, contribute to the analyst's negative outlook on the stock.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares